FacultyFaculty/Author Profile

Tracee Fultz

EY

New York, NY, USA


Tracee Fultz is the Global Leader of the Life Sciences Transfer Pricing Practice in Ernst & Young's International Tax Group and exclusively serves clients in the area of pharmaceutical, biotech and medical device intercompany pricing.
 

Tracee believes in the following principals of tax planning:
  • A company's tax positions should be aligned with its overall corporate and business strategy;
  • The company's tax strategy should be practical enough to implement, sustain and govern, and
  • A company should consider the tax lifecycle of planning, compliance, controversy and governance when setting their planning.

Tracee's experience includes:

  • Planning, documentation and controversy support for 7 out of the top ten medical device companies, measured by revenues.
  • Planning for endomechanical, sutures and meshes affiliates of a large multinational conglomerate
  • Planning, documentation and controversy support for FTSE 100 companies with Irish and UK headquarters
  • Litigation transfer pricing support for 3 of medical devices companies
  • Transaction analysis for largest mergers and acquisitions in the industry

Tracee also serves as a broader healthcare thought leader for Ernst & Young's global pharmaceutical center serving as an advisor to the top 30 accounts in Life Science

She is a member of Ernst & Young's steering committee on healthcare reform for tax and healthcare policy issues. She is often featured on alerts related to healthcare reform and though leadership.

Tracee previously worked as a manager of transfer pricing in Amgen's tax department. She has distinguished herself both within Ernst & Young and in the broader community of the industry as a practical life science specialist who applies industry knowledge and health economics to help companies solve problems. 

Tracee received an M.P.A. in Health Care Management and Policy from New York University focused on healthcare economics. She is a mathematician and health services researcher

She is the co-author of "What Color is Your Swan? Why Biotech Companies Need to Plan (and Expect) the Unexpected," published in the Journal of Biolaw and Business. Her current research focuses on healtheconomics and and pay for performance and includes "The Lifecycle of Oncology Drugs and the Orphan Drug Act", as well as "The Effect of HLA Matching Factor on Racial Disparities of Kidney Transplant Recipients." 

She is the recipient of Healthcare Woman's Business Association's "Rising Star Award" for 2008.

Share
Email

  • FOLLOW PLI:
  • twitter
  • LinkedIn
  • GooglePlus
  • RSS

All Contents Copyright © 1996-2017 Practising Law Institute. Continuing Legal Education since 1933.

© 2017 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.